Specificity and clinical performance of two commercial TRACP 5b immunoassays

Clinical Laboratory

Volumn 55, Issue 5-6, 2009, Pages 223-228

  Ylipahkala, Hannele ^a   Fagerlund, Katja M ^b,c   Janckila, Anthony J ^d   Houston, Brian ^e   Laurie, David ^e   Halleen, Jussi M ^c  

^a SBA Sciences Ltd   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Pharmatest Services Ltd   (Finland)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e IDS Ltd   (United Kingdom)

Author keywords

Alendronate; Bone resorption; Immunoassay; Osteoclast; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; CALCIUM CARBONATE; PLACEBO; TARTRATE RESISTANT ACID PHOSPHATASE 5A; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OSTEOCLAST; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL;

ACID PHOSPHATASE; BONE AND BONES; HUMANS; IMMUNOASSAY; ISOENZYMES; MACROPHAGES; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 69049105333     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänä nen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 2006; 52: 499-509.
2. Janckila AJ, Parthasarathy RN, Parthasarathy LK et al. Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells. J Leukoc Biol 2005; 77: 209-218
3. Hayman AR, Dryden AJ, Chambers TJ, Warburton MJ. Tartrate-resistant acid phosphatase from human osteoclastomas is translated as a single polypeptide. Biochem J 1991; 277: 631-634
4. Ljusberg J, Ek-Rylander B, Andersson G. Tartrate-resistant acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. Biochem J 1999; 343: 63-69 (Pubitemid 29473878)
5. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Yam LT. Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. Clin Chim Acta 2002; 326: 113-122
6. Lam KW, Li CY, Yam LT, Desnick RJ. Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendotheliosis. Clin Biochem 1981; 14: 177-181
7. Kawaguchi T, Nakano T, Sasagawa K, Ohashi T, Miura T, Komoda T. Tartrate-resistant acid phosphatase 5a and 5b contain distinct sugar moieties. Clin Biochem 2008; 41: 1245-1249
8. Halleen JM, Hentunen TA, Karp M, Käkönen S-M, Pettersson K, Väänänen HK. Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res 1998; 13: 683-687 (Pubitemid 28163019)
9. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001; 47: 74-80. (Pubitemid 32064278)
10. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-1345 (Pubitemid 30413866)
11. Ohashi T, Igarashi Y, Mochizuki Y et al. Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 2007; 376: 205-212 (Pubitemid 44889255)
12. Ohashi T, Miura T, Igarashi Y, Sasagawa K, Katayama K. Monoclonal antibody specific to tartrate-resistant acid phosphatase 5b and use thereof. European Patent Application 2003; No 03008868.8.
13. Lam WK, Eastlund DT, Li CY, Yam LT. Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 1978; 24: 1105-1108
14. Uusi-Rasi K, Kannus P, Cheng S et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone 2003; 33: 132-143 (Pubitemid 36952695)
15. Nenonen A, Cheng S, Ivaska KK et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005; 20: 1804-1812 (Pubitemid 41361881)
16. Fagerlund KM, Janckila AJ, Ylipahkala H et al. Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment. Clin Lab 2008; 54: 347-354
17. Janckila AJ, Simons RM, Yam LT. Alternative immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin. Clin Chim Acta 2004; 347: 157-167